Mammographic breast density and hormonal therapy during postmenopause

High criteria of mammographic breast density are the risk factor of breast cancer occurrence. Numerous research papers report that the estrogenic-progestagenic therapy, especially in continuous schema, results in nipple density increase up to 3-6%. Moreover, the literature states that the estrogenic therapy does not cause the increase of MBD. The type of gestagen used seems not to have any influence on breast density, however, estrogen dosage and the age at which the hormonal replacement therapy has been introduced, play crucial role. In most patients from the group of high risk of breast cancer and those treated because of this reason, the use of tamoxifen reduces statistically breast density. Other drugs such as raloxifene or letrozole indicate a decrease of mammographic breast density similar to placebo.